This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Original Research

Zonisamide in the Treatment of Binge Eating Disorder With Obesity: A Randomized Controlled Trial

Susan L. McElroy, M.D.; Renu Kotwal, M.D.; Anna I. Guerdjikova, Ph.D.; Jeffrey A. Welge, Ph.D.; Erik B. Nelson, M.D.; Kathleen A. Lake, M.S.W.; David A. D'Alessio, M.D.; Paul E. Keck, Jr., M.D.; and James I. Hudson, M.D., Sc.D.

Published: December 15, 2006

Article Abstract

Objective: Binge eating disorder (BED) is associated with obesity. Zonisamide is a novel antiepileptic drug associated with weight loss. The purpose of this study was to evaluate zonisamide in the treatment of BED associated with obesity.

Method: In this 16-week, single-center, randomized, double-blind, placebo-controlled, flexible-dose (100-600 mg/day) trial, 60 outpatients with DSM-IV-TR BED received zonisamide (N = 30) or placebo (N = 30). The primary outcome measure was weekly frequency of binge eating episodes. The primary analysis of efficacy was a longitudinal analysis of the intent-to-treat sample, with treatment-by-time interaction as the effect measure. Patients were enrolled from September 5, 2003, through October 1, 2004.

Results: Compared with placebo, zonisamide was associated with a significantly greater rate of reduction in binge eating episode frequency (p = .021), body weight (p < .001), BMI (p = .001), and scores on the Clinical Global Impressions-Severity scale (p < .001), Yale-Brown Obsessive Compulsive Scale Modified for Binge Eating (p < .001), and Three Factor Eating Questionnaire disinhibition scales (p < .001). Plasma ghrelin concentrations increased with zonisamide but decreased with placebo (p = .001). The mean (SD) zonisamide daily dose at endpoint evaluation was 436 (159) mg/day. Twelve patients (N = 8 receiving zonisamide, N = 4 receiving placebo) discontinued because of adverse events. The most common reasons for discontinuing zonisamide were accidental injury with bone fracture (N = 2), psychological complaints (N = 2), and cognitive complaints (N = 2).

Conclusion: Zonisamide was efficacious, but not well tolerated, in the short-term treatment of BED associated with obesity.

Clinical Trials Registration: ClinicalTrials.gov identifier NCT00221442

Volume: 67

Quick Links: Side Effects-Medication , Weight

Continue Reading…

Subscribe to read the entire article

$40.00

Buy this Article as a PDF

References